University of Oxford-founded autoimmune disease therapy developer MiroBio has launched with support from OSI and GlaxoSmithKline’s SR One.

MiroBio, a UK-based immunotherapy developer exploiting University of Oxford research, formally launched yesterday with £27m ($33.1m) in series A funding co-led by the university’s venture fund, Oxford Sciences Innovation (OSI).
Therapeutics-focused venture fund Samsara BioCapital co-led the round, investing alongside SR One, the corporate venturing unit for pharmaceutical company GlaxoSmithKline, and Advent Life Sciences.
Founded in October 2018, MiroBio is working on antibodies for multiple diseases which stimulate specific signals in immune cells in order to modulate the…